VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...

詳細記述

保存先:
書誌詳細
主要な著者: Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Deborah Webb, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis Group 2020-01-01
シリーズ:mAbs
主題:
VHH Antibodies
GPCR
atherosclerosis
BI 655088
biophysical assessment
pharmacokinetic profile
オンライン･アクセス:https://www.tandfonline.com/doi/10.1080/19420862.2019.1709322
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料